Fritextsökning
Artiklar per år
Innehållstyper
-
The TFS family is growing
TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the TFS family welcomes new members.
-
Neolas vd: ”Jag förstod att vi hade något stort på gång”
Hanna Sjöström har gjort en resa från att marknadsföra hud- och hårprodukter och läsk, till att som vd för Neola arbeta med livsavgörande medicinsk teknik för spädbarn. Mot slutet av nästa år planerar företaget att påbörja kommersialiseringen av sin produkt för barn som är för tidigt födda.
-
“We need to keep investing in research and innovation”
Jenni Nordborg has worked for just over four years to highlight life science in Sweden. Her mandate as national coordinator ends in December 2022. ““Life sciences has been a long-term priority of governments since many years and I have no doubt that the ambitions will be strong going forward”, says Jenni Nordborg.
-
Promising Alzheimer’s study data sends Bioarctic stock soaring
The drug candidate lecanemab from Swedish company Bioarctic significantly slowed down the deterioration in patients with early on-set Alzheimer’s, according to preliminary results from a phase III study.
-
Sverige i världstoppen bland innovationsländer
Här kommer ett positivt besked: svenska uppfinnarhjärnor kan fortfarande. Sverige placerar sig på tredje plats på listan över världens mest innovativa länder.
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Business Sweden’s new team is rolling out the blue-yellow carpet
According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta Stenson.
-
Nytt coronavirus upptäckt hos fladdermöss – tog sig förbi vaccin
Ett nytt coronavirus i levande fladdermöss har upptäckts av forskare i USA. Enligt forskarna är viruset resistent mot befintliga covidvaccin.
-
FOKUS Patient turns international
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Biosimilarer ger prispress, men används de tillräckligt?
Biosimilarernas ankomst för drygt 16 år sedan väckte hopp om att många fler patienter skulle få tillgång till effektiva men annars mycket dyra behandlingar med biologiska läkemedel. Så hur bra har svensk sjukvård varit på att använda biosimilarerna? Svaret beror, åtminstone delvis, på vem man frågar.
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.
-
Life Science-podden: The perfect moment for an IPO
When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?
-
Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”
For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the life science sectors of both countries. This year’s event attracted nearly 450 visitors.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.
-
Genes from Neanderthals can affect the correct drug dosage
A fifth of all Europeans carry gene variants inherited from Neanderthals, which cause certain drugs to break down more slowly. This may have implications for the drug doses they should take.
-
Anna Törner: Kalashnikovs in a new guise
Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.
-
Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?
Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.
-
Sweden is heavily criticised for not ordering Covid vaccine
Valneva and the EU Commission have entered into an agreement for 1.25 million doses of the company’s Covid vaccine, but Sweden has not placed an order.
-
Newly discovered gene variant linked to protection against abdominal obesity
American researchers believe they have identified a rare gene mutation that protects against abdominal obesity and metabolic syndrome. The ambition is that the discovery will lead to new treatments that can help reduce the risk of type 2 diabetes and coronary artery disease.
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which
-
Konkurrenskraft, cancervård och MDR – läs krönikörernas tankar om branschen
Nya tankegångar, åsikter och framtidsvisioner från profiler i branschen, tillika krönikörer i Life Science Sweden och vår systertidning Medtech Magazine. Här har vi samlat några av årets krönikor.
-
Tablet treatment for hair loss approved in the USA
The US Drug Administration has given a thumbs up for the first tablet treatment for spotty hair loss.